{
    "clinical_study": {
        "@rank": "159732", 
        "arm_group": [
            {
                "arm_group_label": "Lithium treatment group", 
                "arm_group_type": "Experimental", 
                "description": "Lithium carbonate, 250mg/tablet.  The dose starts with three times a day and one tablet each time for a week.  The daily dose will then be adjusted according to serum lithium level and clinical finding.  Target serum lithium level is 0.6 - 1.2mmol/L."
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The dose of the placebo will be adjusted according to the dummy serum level report."
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the efficacy of lithium carbonate in the treatment of neuropathic pain of\n      patients with spinal cord injury."
        }, 
        "brief_title": "Study to Evaluate the Efficacy of Lithium Carbonate in Spinal Cord Injury Patients With Neuropathic Pain", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neuropathic Pain", 
            "Neuralgia", 
            "Spinal Cord Injuries"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neuralgia", 
                "Spinal Cord Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, placebo-controlled, double-blinded trial.  Sixty spinal cord injured\n      subjects with neuropathic pain will be randomized into two groups.  The subject in the\n      Treatment Group will receive lithium carbonate, while the Control Group will receive\n      placebo.  Neither the subjects nor the physicians know which group the subjects are\n      allocated.\n\n      Each subject will receive 6 weeks oral lithium carbonate or placebo.   In the Treatment\n      Group, the dose will be adjusted according to the serum lithium level.  While in the Control\n      Group, the dose will be adjusted based on a dummy serum level report.\n\n      The out come will be assessed during visits at 1 week, 2 weeks 6 weeks and 12 weeks, and a\n      phone call follow-up of 24 weeks after the start of the medication.  The primary outcome\n      measure is the severity level of pain.  The efficacy and safety will be analyzed by\n      comparing the results of the Treatment Group with those of the Control Group"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 - 65;\n\n          -  Diagnosis of traumatic spinal cord injury;\n\n          -  Clinically diagnosed neuropathic pain;\n\n          -  Pain severity is at least 4 on a 11-point numeric rating scale at screening;\n\n          -  Pain present regularly for at least 6 weeks before enrollment;\n\n          -  Able to understand instructions and provide reliable pain assessments;\n\n          -  Subjects who are voluntarily signed and dated an IEC approved informed consent form;\n\n        Exclusion Criteria:\n\n          -  Significant renal, cardiovascular, hepatic, infectious or psychiatric disease;\n\n          -  Significant brain injury with neurological deficits;\n\n          -  Debilitation or dehydration;\n\n          -  Addison's disease;\n\n          -  Recent (within 1 week) or current use of anti-diuretics or other drugs that interacts\n             with lithium, such as tricyclic antidepressants, NSAIDs and tetracyclines;\n\n          -  A history of substance or alcohol abuse within past 1 year;\n\n          -  A need for elective surgery involving preoperative or postoperative analgesics or\n             anesthetics during the study period;\n\n          -  Current pregnant or breast feeding, or female who has childbearing potential but is\n             not willing to use an approved method of birth control;\n\n          -  Participation in any drug study in the last three months;\n\n          -  History of oral lithium intake for any reason; or\n\n          -  any criteria, which in the opinion of the investigator, suggests that the subject\n             would not be compliant with the study protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855594", 
            "org_study_id": "CN302"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lithium treatment group", 
                "description": "250mg/tablet, 6 weeks course of lithium carbonate", 
                "intervention_name": "Lithium Carbonate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Control group", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lithium", 
                "Lithium Carbonate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 27, 2014", 
        "location": [
            {
                "contact": {
                    "email": "405510627@qq.com", 
                    "last_name": "Rui Wang, MD", 
                    "phone": "+86 029 81306435"
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shanxi"
                    }, 
                    "name": "Xi'an Jiaotong University Second Affiliated Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Xijing He, M.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Rui Wang, M.D,", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mingliang.yang@sohu.com", 
                    "last_name": "Mingliang Yang, M.D.", 
                    "phone": "+86 010 87569088"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "China Rehabilitation Research Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Mingliang Yang, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jianjun Li, M.D,", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double Blind, Randomized Placebo-controlled Clinical Study Evaluating the Efficacy of Lithium Carbonate in the Treatment of Neuropathic Pain of Patients With Spinal Cord Injury", 
        "overall_contact": {
            "email": "general@chinascinet.org", 
            "last_name": "Wise Young, Ph.D., M.D.", 
            "phone": "+852 28660809"
        }, 
        "overall_official": [
            {
                "affiliation": "Xi'an Jiaotong University Second Affiliated Hospital", 
                "last_name": "Xijing He, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "China Rehabilitaition Research Center", 
                "last_name": "Jianjun Li, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "pain severity level", 
            "measure": "Change from Baseline in Numeric Rating Scale (NRS) at 24 weeks", 
            "safety_issue": "No", 
            "time_frame": "D0, Wk 1, 2, 6, 12, and 24"
        }, 
        "reference": [
            {
                "PMID": "22105463", 
                "citation": "Yang ML, Li JJ, So KF, Chen JY, Cheng WS, Wu J, Wang ZM, Gao F, Young W. Efficacy and safety of lithium carbonate treatment of chronic spinal cord injuries: a double-blind, randomized, placebo-controlled clinical trial. Spinal Cord. 2012 Feb;50(2):141-6. doi: 10.1038/sc.2011.126. Epub 2011 Nov 22."
            }, 
            {
                "PMID": "20531359", 
                "citation": "Wong YW, Tam S, So KF, Chen JY, Cheng WS, Luk KD, Tang SW, Young W. A three-month, open-label, single-arm trial evaluating the safety and pharmacokinetics of oral lithium in patients with chronic spinal cord injury. Spinal Cord. 2011 Jan;49(1):94-8. doi: 10.1038/sc.2010.69. Epub 2010 Jun 8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855594"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in multidimensional pain inventory life interference subscale (MPI-LIS)", 
                "safety_issue": "No", 
                "time_frame": "D0, Wk 1, 2, 6, 12 and 24"
            }, 
            {
                "measure": "Change in Short-Form 36 single question", 
                "safety_issue": "No", 
                "time_frame": "D0, Wk 1, 2, 6, 12, and 24"
            }, 
            {
                "measure": "Change in Sleep interference assessment score", 
                "safety_issue": "No", 
                "time_frame": "D0, Wk 1, 2, 6, 12 and 24"
            }, 
            {
                "measure": "Change in Weekly number of days with pain attack", 
                "safety_issue": "No", 
                "time_frame": "D0, Wk 1, 2, 6, 12 and 24"
            }, 
            {
                "measure": "Change in the Patient global impression of change (PGIC)", 
                "safety_issue": "No", 
                "time_frame": "Wk 1, 2, 6, and 12"
            }, 
            {
                "measure": "Change in PHQ-9", 
                "safety_issue": "No", 
                "time_frame": "D0, Wk 1, 2, 6 and 12"
            }, 
            {
                "measure": "Change in AISA sensory scores, motor scores and AISA impairment scale", 
                "safety_issue": "No", 
                "time_frame": "D0, Wk 6 and 12"
            }, 
            {
                "measure": "Change in Modified Ashworth Scale", 
                "safety_issue": "No", 
                "time_frame": "D0, Wk 6 and 12"
            }, 
            {
                "measure": "Magnetic resonance diffusion tensor imaging (optional)", 
                "safety_issue": "No", 
                "time_frame": "D0, Wk 6 and 12"
            }, 
            {
                "measure": "Electrophysiology (optional)", 
                "safety_issue": "No", 
                "time_frame": "D0, Wk 6 and 12"
            }
        ], 
        "source": "China Spinal Cord Injury Network", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "China Rehabilitation Research Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Second Affiliated Hospital of Xi'an Jiaotong University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "China Spinal Cord Injury Network", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}